全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...
PLOS Medicine  2016 

Strategies to Prevent Cholera Introduction during International Personnel Deployments: A Computational Modeling Analysis Based on the 2010 Haiti Outbreak

DOI: 10.1371/journal.pmed.1001947

Full-Text   Cite this paper   Add to My Lib

Abstract:

Background Introduction of Vibrio cholerae to Haiti during the deployment of United Nations (UN) peacekeepers in 2010 resulted in one of the largest cholera epidemics of the modern era. Following the outbreak, a UN-commissioned independent panel recommended three pre-deployment intervention strategies to minimize the risk of cholera introduction in future peacekeeping operations: screening for V. cholerae carriage, administering prophylactic antimicrobial chemotherapies, or immunizing with oral cholera vaccines. However, uncertainty regarding the effectiveness of these approaches has forestalled their implementation by the UN. We assessed how the interventions would have impacted the likelihood of the Haiti cholera epidemic. Methods and Findings We developed a stochastic model for cholera importation and transmission, fitted to reported cases during the first weeks of the 2010 outbreak in Haiti. Using this model, we estimated that diagnostic screening reduces the probability of cases occurring by 82% (95% credible interval: 75%, 85%); however, false-positive test outcomes may hamper this approach. Antimicrobial chemoprophylaxis at time of departure and oral cholera vaccination reduce the probability of cases by 50% (41%, 57%) and by up to 61% (58%, 63%), respectively. Chemoprophylaxis beginning 1 wk before departure confers a 91% (78%, 96%) reduction independently, and up to a 98% reduction (94%, 99%) if coupled with vaccination. These results are not sensitive to assumptions about the background cholera incidence rate in the endemic troop-sending country. Further research is needed to (1) validate the sensitivity and specificity of rapid test approaches for detecting asymptomatic carriage, (2) compare prophylactic efficacy across antimicrobial regimens, and (3) quantify the impact of oral cholera vaccine on transmission from asymptomatic carriers. Conclusions Screening, chemoprophylaxis, and vaccination are all effective strategies to prevent cholera introduction during large-scale personnel deployments such as that precipitating the 2010 Haiti outbreak. Antimicrobial chemoprophylaxis was estimated to provide the greatest protection at the lowest cost among the approaches recently evaluated by the UN.

References

[1]  Ali M, Lopez AL, Ae You Y, Eun Kim Y, Sah B, et al. The global burden of cholera. Bull World Health Organ. 2012;90: 209–218. doi: 10.2471/BLT.11.093427. pmid:22461716
[2]  Ministère de la santé publique et de la population. Rapport cholera 01 mars 2015. .
[3]  Jenson D, Szabo V. Cholera in Haiti and other Caribbean regions, 19th century. Emerg Infect Dis. 2011;17: 2130–2135. doi: 10.3201/eid1711.110958. pmid:22099117
[4]  Orata FD, Keim PS, Boucher Y. The 2010 cholera outbreak in Haiti: how science solved a controversy. PLoS Pathog. 2014;10: e1003967 doi: 10.1371/journal.ppat.1003967. pmid:24699938
[5]  Katz LS, Petkau A, Beaulaurier J, Tyler S, Antonova ES, et al. Evolutionary dynamics of Vibrio cholerae O1 following a single-source introduction to Haiti. mBio. 2013;4:e00398–13. doi: 10.1128/mBio.00398-13. pmid:23820394
[6]  Piarroux R, Barrais R, Faucher BB, Haus R, Piarroux M, et al. Understanding the cholera epidemic, Haiti. Emerg Infect Dis. 2011;17:1161–1167. doi: 10.3201/eid1707.110059. pmid:21762567
[7]  Lantagne D, Balakrish Nair G, Lanata CF, Cravioto A. The cholera outbreak in Haiti: Where and how did it begin? Curr Top Microbiol Immunol. 2013;379:145–164. doi: 10.1007/82_2013_331
[8]  Nelson EJ, Nelson DS, Salam MA, Sack DA. Antibiotics for both moderate and severe cholera. N Engl J Med. 2011;364:5–7. doi: 10.1056/NEJMp1013771. pmid:21142691
[9]  Reveiz L, Chapman E, Ramon-Pardo P, Koehlmoos TP, Cuervo LG, et al. Chemoprophylaxis in contacts of patients with cholera: systematic review and meta-analysis. PLoS ONE. 2011;6:e2760. doi: 10.1371/journal.pone.0027060
[10]  Sanchez JL, Vasquez B, Begue RE, Meza R, Castellares G, et al. Protective efficacy of oral whole-cell/recombinant-B-subunit cholera vaccine in Peruvian military recruits. Lancet. 1994;344:1273–1276. pmid:7967990 doi: 10.1016/s0140-6736(94)90755-2
[11]  Black RE, Levine MM, Clements ML, Young CR, Svennerholm AM, et al. Protective efficacy in humans of killed whole-vibrio oral cholera vaccine with and without the B subunit of cholera toxin. Infect Immun. 1987;55:1116–1120. pmid:3552989
[12]  United Nations follow-up to the recommendations of the Independent Panel of Expertos on the Cholera Outbreak in Haiti. .
[13]  Medrano Rojas P. Assistant Secretary General’s response. .
[14]  Hughes JM, Boyce JM, Levine RJ, Khan M, Aziz KM, et al. Epidemiology of El Tor cholera in rural Bangladesh: importance of surface water in transmission. Bull World Health Organ. 1982;60:395–404. pmid:6982775
[15]  Bart KJ, Huq Z, Khan M, Mosley WH. Seroepidemiologic studies during a simultaneous epidemic of infection with El Tor Ogawa and classical Inaba Vibrio cholerae. J Infect Dis. 1970;121:17–24. pmid:4912068 doi: 10.1093/infdis/121.supplement.s17
[16]  Woodward WE, Mosley WH. The spectrum of cholera in rural Bangladesh: comparison of El Tor Ogawa and classical Inaba infection. Am J Epidemiol. 1972;96:342–351. pmid:4564735
[17]  Tamayo JF, Mosley WH, Alvero MG, Joseph PR, Gomez CZ, et al. Studies of cholera El Tor in the Philippines. Bull World Health Organ. 1965;33:645–649. pmid:5295145
[18]  Glass RI, Holmgren J, Haley CE, Khan MR, Svennerholm AM, et al. Predisposition for cholera of individuals with O blood group. Possible evolutionary significance. Am J Epidemiol. 1985;121: 791–796. pmid:4014172
[19]  Weil AA, Khan AI, Chowdhury F, Larocque RC, Faruque ASG, et al. Clinical outcomes in household contacts of patients with cholera in Bangladesh. Clin Infect Dis. 2009;49: 1473–1479. doi: 10.1086/644779. pmid:19842974
[20]  Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw. 2010;36: 1–48. doi: 10.18637/jss.v036.i03
[21]  Ernst S, Weinrobe C, Bien-Aime C, Rawson I. Cholera management and prevention at H?pital Albert Schweitzer, Haiti. Emerg Infect Dis. 2011;17: 2155–2157. doi: 10.3201/eid1711.110815. pmid:22099123
[22]  Update: outbreak of cholera—Haiti, 2010. Morbid Mortal Wkly Rep. 2010;59:1586–1590.
[23]  Grad YH, Miller JC, Lipsitch M. Cholera modeling: challenges to quantitative analysis and predicting the impact of interventions. Epidemiology. 2012;23: 523–530. doi: 10.1097/EDE.0b013e3182572581. pmid:22659546
[24]  Chao DL, Longini IM, Morris JG. Modeling cholera outbreaks. Curr Top Microbiol Immunol. 2014;379: 195–209. doi: 10.1007/82_2013_307. pmid:23412687
[25]  Gaudart J, Rebaudet S, Barrais R, Boncy J, Faucher B, et al. Spatio-temporal dynamics of cholera during the first year of the epidemic in Haiti. PLoS Negl Trop Dis. 2013;7: e0002145. doi: 10.1371/journal.pntd.0002145
[26]  Barzilay EJ, Schaad N, Magloire R, Mung KS, Boncy J, et al. Cholera surveillance during the Haiti epidemic—the first 2 years. N Engl J Med. 2013;368: 599–609. doi: 10.1056/NEJMoa1204927. pmid:23301694
[27]  Azman AS, Rudolph KE, Cummings DAT, Lessler J. The incubation period of cholera: A systematic review. J Infect. 2013;66: 432–438. doi: 10.1016/j.jinf.2012.11.013. pmid:23201968
[28]  Alam NH, Ashraf H, Khan WA, Karim MM, Fuchs GJ. Efficacy and tolerability of racecadotril in the treatment of cholera in adults: a double blind, randomised, controlled clinical trial. Gut. 2003;52: 1419–1423. pmid:12970133 doi: 10.1136/gut.52.10.1419
[29]  Dutta D, Bhattacharya SK, Bhattacharya MK, Deb A, Deb M, et al. Efficacy of norfloxacin and doxycycline for treatment of Vibrio cholerae O139 infection. J Antimicrob Chemother. 1996;37: 575–581. pmid:9182114 doi: 10.1093/jac/37.3.575
[30]  Leibovici-Weissman Y, Neuberger A, Bitterman R, Sinclair D, Salam MA, et al. Antimicrobial drugs for treating cholera. Cochrane database Syst Rev. 2014;6: CD008625 doi: 10.1002/14651858.CD008625.pub2. pmid:24944120
[31]  Patra FC, Majumder RN, Eeckels R, Desjeux JF, Mahalanabis D. Sacolene in cholera: a double blind randomized controlled trial. Scand J Infect Dis. 1999;31: 151–154. pmid:10447324 doi: 10.1080/003655499750006191
[32]  Rabbani GH, Islam MR, Butler T, Shahrier M, Alam K. Single-dose treatment of cholera with furazolidone or tetracycline in a double-blind randomized trial. Antimicrob Agents Chemother. 1989;33: 1447–1450. pmid:2684006 doi: 10.1128/aac.33.9.1447
[33]  Lindenbaum J, Greenough WB, Islam MR. Antibiotic therapy of cholera. Bull World Health Organ. 1967;36: 871–883. pmid:4865453
[34]  Shahadat Hossain M, Salam MA, Rabbani GH, Kabir I, Biswas R, et al. Tetracycline in the treatment of severe cholera due to Vibrio cholerae O139 Bengal. J Heal Popul Nutr. 2002;20: 18–25.
[35]  Hartley DM, Morris JG, Smith DL. Hyperinfectivity: A critical element in the ability of V. cholerae to cause epidemics?. PLoS Med. 2006;3: 63–69. doi: 10.1371/journal.pmed.0030007
[36]  Merrell DS, Butler SM, Qadri F, Dolganov Na, Alam A, et al. Host-induced epidemic spread of the cholera bacterium. Nature. 2002;417: 642–645. pmid:12050664 doi: 10.1038/nature00778
[37]  Alam A, Larocque RC, Harris JB, Vanderspurt C, Ryan ET, et al. Hyperinfectivity of Human-Passaged Vibrio cholerae can be modeled by growth in the infant mouse. Infect Immun. 2005;73: 6674–6679. pmid:16177344 doi: 10.1128/iai.73.10.6674-6679.2005
[38]  Cash RA, Music SI, Libonati JP, Snyder MJ, Wenzel RP, et al. Response of man to infection with Vibrio cholerae. Clinical, serologic, and bacteriologic responses to a known inoculum. J Infect Dis. 1974;129: 45–52. pmid:4809112 doi: 10.1093/infdis/129.1.45
[39]  Sack DA, Tacket CO, Cohen MB, Sack RB, Losonsky Ga., et al. Validation of a volunteer model of cholera with frozen bacteria as the challenge. Infect Immun. 1998;66: 1968–1972. pmid:9573077
[40]  Rendtorff RC, Kashgarian M. Stool patterns of healthy adult males. Dis Colon Rectum. 1953;10: 222–228. doi: 10.1007/bf02617184
[41]  Haiti 2009 population data, section estimates, stratified by age and sex. Centers for Disease Control and Prevention 2012. .
[42]  Clements ML, Levine MM, Young CR, Black RE, Lim YL, et al. Magnitude, kinetics, and duration of vibriocidal antibody responses in North Americans after ingestion of Vibrio cholerae. J Infect Dis. 1982;145: 465–473. pmid:7069227 doi: 10.1093/infdis/145.4.465
[43]  Jackson BR, Talkington DF, Pruckler JM, Fouché MDB, Lafosse E, et al. Seroepidemiologic survey of epidemic cholera in Haiti to assess spectrum of illness and risk factors for severe disease. Am J Trop Med Hyg. 2013;89: 654–664. doi: 10.4269/ajtmh.13-0208. pmid:24106192
[44]  Chao DL, Halloran ME, Longini IM. Vaccination strategies for epidemic cholera in Haiti with implications for the developing world. Proc Natl Acad Sci U S A. 2011;108: 7081–7085. doi: 10.1073/pnas.1102149108. pmid:21482756
[45]  Bhuiyan NA, Qadri F, Faruque ASG, Malek MA, Salam MA, et al. Use of dipsticks for rapid diagnosis of cholera caused by Vibrio cholerae O1 and O139 from rectal swabs. J Clin Microbiol. 2003;41: 3939–3941. pmid:12904424 doi: 10.1128/jcm.41.8.3939-3941.2003
[46]  Chakraborty S, Alam M, Scobie HM, Sack DA. Adaptation of a simple dipstick test for detection of Vibrio cholerae O1 and O139 in environmental water. Front Microbiol. 2013;4: 1–3. doi: 10.3389/fmicb.2013.00405
[47]  Dick MH, Guillerm M, Moussy F, Chaignat CL. Review of two decades of cholera diagnostics: how far have we really come? PLoS Negl Trop Dis. 2012;6: e0001845. doi: 10.1371/journal.pntd.0001845
[48]  McCormack WM, Chowdhury AM, Jahangir N. Tetracycline prophylaxis in families of cholera patients. Bull World Health Organ. 1967;38: 787–792
[49]  Saha D, Karim MM, Khan WA, Ahmed S, Salam MA, et al. Single-dose azithromycin for the treatment of cholera in adults. N Engl J Med. 2006;354: 2452–2462. pmid:16760445 doi: 10.1056/nejmoa054493
[50]  Levine M, Herrington D, Losonsky G, Tall B, Kaper J, et al. Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR. Lancet. 1988;332: 467–470. doi: 10.1016/s0140-6736(88)90120-1
[51]  Shin S, Desai SN, Sah BK, Clemens JD. Oral vaccines against cholera. Clin Infect Dis. 2011;52: 1343–1349. doi: 10.1093/cid/cir141. pmid:21498389
[52]  Echevarría J, Seas C, Carrillo C, Mostorino R, Ruiz R, et al. Efficacy and tolerability of ciprofloxacin prophylaxis in adult household contacts of patients with cholera. Clin Infect Dis. 1995;20: 1480–1484. pmid:7548495 doi: 10.1093/clinids/20.6.1480
[53]  International Drug Price Indicator Guide. Medford, Massachusetts, US: Management Sciences for Health. 2014.
[54]  Guidance on how to access the Oral Cholera Vaccine (OCV) from the ICG emergency stockpile. .
[55]  Gillespie DT. Exact stochastic simulation of coupled chemical reactions. J Phys Chem. 1977;81: 2340–2361. doi: 10.1021/j100540a008
[56]  Van Den Driessche P, Watmough J. Reproduction numbers and sub-threshold endemic equilibria for compartmental models of disease transmission. Math Biosci. 2002;180: 29–48. pmid:12387915 doi: 10.1016/s0025-5564(02)00108-6
[57]  Ivers LC, Walton DA. The “first” case of cholera in Haiti: Lessons for global health. Am J Trop Med Hyg. 2012;86: 36–38. doi: 10.4269/ajtmh.2012.11-0435. pmid:22232448
[58]  Harris JR, Cavallaro EC, De Nóbrega AA, Jean JCB, Bopp C, et al. Field evaluation of crystal VC rapid dipstick test for cholera during a cholera outbreak in Guinea-Bissau. Trop Med Int Heal. 2009;14: 1117–1121. doi: 10.1111/j.1365-3156.2009.02335.x
[59]  Crystal VC (Dipstick) immunochromatographic test for detection of V. cholerae in stool (rapid test). SPAN Diagnostics. .
[60]  Farmer P, Almazor CP, Bahnsen ET, Barry D, Bazile J, et al. Meeting Cholera’s challenge to Haiti and the world: A joint statement on cholera prevention and care. PLoS Negl Trop Dis. 2011;5: e0001145. doi: 10.1371/journal.pntd.0001145
[61]  Chretien JP, Blazes DL, Coldren RL, Lewis MD, Gaywee J, et al. The importance of militaries from developing countries in global infectious disease surveillance. Bull World Health Organ. 2007;85: 174–180. pmid:17486207 doi: 10.2471/blt.06.037101
[62]  Steffen R. Immunization of peacekeeping forces. Emerg Infect Dis. 1999;5: 485–486. pmid:10341196 doi: 10.3201/eid0503.990331
[63]  Okeke IN, Aboderin OA, Byarugaba DK, Ojo KK, Opintan JA. Growing problem of multidrug-resistant enteric pathogens in Africa. Emerg Infect Dis. 2007;13: 1640–1646. doi: 10.3201/eid1311.070674. pmid:18217545
[64]  Faruque ASG, Alam K, Malek Ma, Khan MGY, Ahmed S, et al. Emergence of multidrug-resistant strain of Vibrio cholerae OI in Bangladesh and reversal of their susceptibility to tetracycline after two years. J Heal Popul Nutr. 2007;25: 241–243.
[65]  Harris JB, LaRocque RC, Qadri F, Ryan ET, Calderwood SB. Cholera. Lancet. 2012;379: 2466–2476. doi: 10.1016/S0140-6736(12)60436-X. pmid:22748592
[66]  Chin CS, Sorenson J, Harris JB, Robins WP, Charles RC, et al. The origin of the Haitian cholera outbreak strain. N Engl J Med. 2011;364: 33–42. doi: 10.1056/NEJMoa1012928. pmid:21142692
[67]  Ali A, Chen Y, Johnson JA, Redden E, Mayette Y, et al. Recent clonal origin of cholera in Haiti. Emerg Infect Dis. 2011;17: 699–701. doi: 10.3201/eid1704.101973. pmid:21470464
[68]  Constantin de Magny G, Murtugudde R, Sapiano MRP, Nizam A, Brown CW, et al. Environmental signatures associated with cholera epidemics. Proc Natl Acad Sci U S A. 2012;105: 17676–17681. doi: 10.1073/pnas.0809654105
[69]  Azman AS, Luquero FJ, Ciglenecki I, Grais RF, Sack Da., et al. The Impact of a One-Dose versus Two-Dose Oral Cholera Vaccine Regimen in Outbreak Settings: A Modeling Study. PLoS Med. 2015;12: e1001867. doi: 10.1371/journal.pmed.1001867. pmid:26305226
[70]  Reyburn R, Deen JL, Grais RF, Bhattacharya SK, Sur D, et al. The case for reactive mass oral cholera vaccinations. PLoS Negl Trop Dis. 2011;5: e952. doi: 10.1371/journal.pntd.0000952. pmid:21283614
[71]  Houston S, Houston A. Screening and Treating UN Peacekeepers to Prevent the Introduction of Artemisinin-Resistant Malaria into Africa. PLoS Med. 2015;12: e1001822. doi: 10.1371/journal.pmed.1001822. pmid:25942008
[72]  Watson JT, Gayer M, Connolly MA. Epidemics after natural disasters. Emerg Infect Dis. 2007;13: 1–5. pmid:17370508 doi: 10.3201/eid1301.060779
[73]  Dowell SF, Braden CR. Implications of the introduction of cholera to Haiti. Emerg Infect Dis. 2011;17: 1299–1300. pmid:21762593 doi: 10.3201/eid1707.110625
[74]  United Nations Peacekeeping. Troop and police contributors. .

Full-Text

comments powered by Disqus

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133